interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Resmetirom

Generic competition · all medicines · read 12 November 2026

Is there a generic of Resmetirom, and who makes it?

Resmetirom appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Resmetirom1 dosage-form group in the Orange Book
0generic makers listed
  1. Resmetirom appears in 1 dosage-form group in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 1 group has a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Tablet, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Rezdiffra. No generic is listed as marketed.

20202025203020352040204501brand 2024data datePatent 7452882 listed to expire 12 September 2027Patent 11986481 listed to expire 17 September 2033Patent 11564926 listed to expire 17 September 2033Patent 10376517 listed to expire 17 September 2033Patent 9266861 listed to expire 17 September 2033Patent 12661359 listed to expire 28 January 2042Patent 12667575 listed to expire 4 February 2045Patent 12377104 listed to expire 4 February 2045Exclusivity NCE to 14 March 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 14 March 2029Exclusivity NCE Rezdiffra
  • 12 September 2027Patent 7452882 drug substance
  • 17 September 2033Patent 11986481
  • 17 September 2033Patent 11564926 drug substance
  • 17 September 2033Patent 10376517
  • 17 September 2033Patent 9266861 drug substance
  • 28 January 2042Patent 12661359
  • 4 February 2045Patent 12667575
  • 4 February 2045Patent 12377104

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.